Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group., Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S.

Nature. 2012 Apr 18;486(7403):346-52. doi: 10.1038/nature10983.

2.

The genetic basis for cancer treatment decisions.

Dancey JE, Bedard PL, Onetto N, Hudson TJ.

Cell. 2012 Feb 3;148(3):409-20. doi: 10.1016/j.cell.2012.01.014. Review.

3.
4.

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.

Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, Hu K, Le QT, Colevas AD, Glisson BS, Chan AT, Ang KK.

Lancet Oncol. 2012 Feb;13(2):172-80. doi: 10.1016/S1470-2045(11)70303-5. Epub 2011 Dec 15.

5.

Activation of AKT is associated with metastasis of nasopharyngeal carcinoma.

Liu Y, Chen LH, Yuan YW, Li QS, Sun AM, Guan J.

Tumour Biol. 2012 Feb;33(1):241-5. doi: 10.1007/s13277-011-0272-4. Epub 2011 Nov 25.

PMID:
22116667
6.

Integrated analysis of multiple gene expression profiling datasets revealed novel gene signatures and molecular markers in nasopharyngeal carcinoma.

Huang C, Tang H, Zhang W, She X, Liao Q, Li X, Wu M, Li G.

Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):166-75. doi: 10.1158/1055-9965.EPI-11-0593. Epub 2011 Nov 8.

7.

Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival.

Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MK, Chen G, Cheah SL, Lee M, Liu ZW, Chen J, Zhang JX, Zhang HZ, He JH, Chen FL, Zhu XD, Huang MY, Liao DZ, Fu J, Shao Q, Cai MB, Du ZM, Yan LX, Hu CF, Ng HK, Wee JT, Qian CN, Liu Q, Ernberg I, Ye W, Adami HO, Chan AT, Zeng YX, Shao JY.

J Clin Oncol. 2011 Dec 1;29(34):4516-25. doi: 10.1200/JCO.2010.33.7741. Epub 2011 Oct 24. Erratum in: J Clin Oncol. 2012 Feb 20;30(6):679.

PMID:
22025164
8.

A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.

Ma BB, Kam MK, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong H, Yu BK, Ahuja A, Chan AT.

Ann Oncol. 2012 May;23(5):1287-92. doi: 10.1093/annonc/mdr401. Epub 2011 Sep 23.

PMID:
21948811
9.

Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy.

Kim YJ, Go H, Wu HG, Jeon YK, Park SW, Lee SH.

Head Neck. 2011 Oct;33(10):1458-66. doi: 10.1002/hed.21611. Epub 2010 Nov 4.

PMID:
21928418
10.

Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics.

Ruan L, Li XH, Wan XX, Yi H, Li C, Li MY, Zhang PF, Zeng GQ, Qu JQ, He QY, Li JH, Chen Y, Chen ZC, Xiao ZQ.

Proteome Sci. 2011 Jun 28;9:35. doi: 10.1186/1477-5956-9-35.

11.

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, Zaramboukas T, Nikolaou A, Markou K, Resiga L, Dionysopoulos D, Samantas E, Athanassiou H, Misailidou D, Skarlos D, Ciuleanu T.

Ann Oncol. 2012 Feb;23(2):427-35. doi: 10.1093/annonc/mdr116. Epub 2011 Apr 27.

PMID:
21525406
12.

Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta.

Kung CP, Meckes DG Jr, Raab-Traub N.

J Virol. 2011 May;85(9):4399-408. doi: 10.1128/JVI.01703-10. Epub 2011 Feb 9.

13.

The cadherin-catenin complex in nasopharyngeal carcinoma.

Galera-Ruiz H, Ríos MJ, González-Cámpora R, de Miguel M, Carmona MI, Moreno AM, Galera-Davidson H.

Eur Arch Otorhinolaryngol. 2011 Sep;268(9):1335-41. doi: 10.1007/s00405-010-1464-z. Epub 2011 Jan 15.

14.

Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma.

Cao XJ, Hao JF, Yang XH, Xie P, Liu LP, Yao CP, Xu J.

Med Oncol. 2012 Mar;29(1):263-71. doi: 10.1007/s12032-010-9782-y. Epub 2011 Jan 8.

PMID:
21221850
15.

Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3β-Cyclin D1 pathway.

Ong CS, Zhou J, Ong CN, Shen HM.

Cancer Lett. 2010 Dec 8;298(2):167-75. doi: 10.1016/j.canlet.2010.07.001. Epub 2010 Jul 23.

PMID:
20655656
16.

Epstein-Barr virus latent membrane protein-2A-induced DeltaNp63alpha expression is associated with impaired epithelial-cell differentiation.

Fotheringham JA, Mazzucca S, Raab-Traub N.

Oncogene. 2010 Jul 29;29(30):4287-96. doi: 10.1038/onc.2010.175. Epub 2010 May 24.

17.

Prognostic significance of clinical parameters and Epstein-Barr virus infection in non-endemic undifferentiated carcinoma of nasopharyngeal type: a Serbian report.

Terzic TT, Boricic MI, Pendjer IP, Ruzic Zecevic DT, Tomanovic NR, Brasanac DC, Boricic IV.

Med Oncol. 2011 Dec;28(4):1325-30. doi: 10.1007/s12032-010-9551-y. Epub 2010 May 6.

PMID:
20446059
18.

[Expression and relationship of EBV LMP1, COX-2 and VEGF-C in nasopharyngeal carcinoma].

Yi X, Tang A, Qin Y, Wen W, Zhao W.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Feb;24(3):126-8. Chinese.

PMID:
20429385
19.

Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma.

Chen J, Hu CF, Hou JH, Shao Q, Yan LX, Zhu XF, Zeng YX, Shao JY.

J Transl Med. 2010 Mar 26;8:30. doi: 10.1186/1479-5876-8-30.

20.

High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.

Lee HW, Hwang YH, Han JH, Choi JH, Kang SY, Jeong SH, Ann MS, Oh YT, Kim JH, Kim CH, Sheen SS.

Oral Oncol. 2010 Mar;46(3):209-13. doi: 10.1016/j.oraloncology.2009.12.007. Epub 2010 Feb 11.

PMID:
20153243

Supplemental Content

Support Center